SciELO - Scientific Electronic Library Online

 
vol.24 número5Características clínicas, angiográficas y desenlaces clínicos en adultos mayores de 65 años con síndrome coronario agudo sin elevación del segmento STAplicación de las escalas de estratificación del riesgo en el diagnóstico de los síndromes coronarios agudos índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Colombiana de Cardiología

versión impresa ISSN 0120-5633

Resumen

M. SENIOR, Juan; MUNOZ, Edison  y  DIAZ, James. Effect of inotropic drugs on mortality in acute heart failure. Network meta-analysis of clinical trials. Rev. Colomb. Cardiol. [online]. 2017, vol.24, n.5, pp.468-479.  Epub 16-Mayo-2017. ISSN 0120-5633.  http://dx.doi.org/10.1016/j.rccar.2017.01.003.

Introduction:

Inotropic drugs are required in order to stabilise patients with acute heart failure.

Objective:

To determine which of the inotropic drugs are associated with lower mortality.

Materials and method:

A network meta-analysis was performed using the frequentist approach. The systematic search included PUBMED, EMBASE, CENTRAL, DARE, Epistemonikos, ScieELO, LILACS, and OpenGray data bases. Randomised clinical trials were included that provided data on mortality on patients with acute heart failure who received dobutamine, levosimendan or milrinone.

Results:

A total of 5,315 patients in the 20 studies include were randomly assigned to five comparisons. The majority of the studies showed bias risks in population selection and in the blinding of the intervention. The different comparisons with placebo, dobutamine (OR 1.30; 95% probability interval (PI); 0.54-3.09), levosimendan (OR 0.86; 95% PI; 0.38-1.93), and milrinone (OR 1.69; 95% PI; 0.49-5.85), did not show any statistically significant differences. The same applied to the comparisons between themselves, dobutamine vs. levosimendan (OR 0.66; 95%PI; 0.30-1.48), dobutamine vs. milrinone (OR 1.30; 95% PI; 0.34-4.96), and levosimendan vs. milrinone (OR 1.97; 95% PI; 0.53-7.29). The analysis by ranges showed a higher probability for milrinone, followed by dobutamine.

Discussion:

There are no differences in the use of inotropic drugs, such as dobutamine, levosimendan or milrinone in terms of mortality outcomes. Their use, therefore, will depend on other factors.

Palabras clave : Heart failure; Inotropes; Meta-analysis.

        · resumen en Español     · texto en Español     · Español ( pdf )